Clinical immunotherapy for brain tumors.

Journal Article (Review)

As an immunization platform for brain tumors, dendritic cells supply an impressive host of advantages. On the simplest level, they provide the safety and tumor-specificity so wanted by current therapeutic options. Yet, in addition, as the fundamental antigen-presenting cell, they circumvent many of the immunologic challenges that gliomas and the CNS proffer and that other immunotherapeutic modes fail to overcome. Directions to take now include the identification of new tumor-specific and tumor-associated antigens; the determination of the optimal dendritic cell subtype, generation, loading method, maturation state, dose, and route of delivery for immunizations; the further characterization of dendritic cells and their activities; and, potentially, the discovery of ways to pulse dendritic cells efficiently in vivo. Preclinical studies continue to play an important role in refining this form of active immunotherapy.

Full Text

Duke Authors

Cited Authors

  • Fecci, PE; Sampson, JH

Published Date

  • November 2002

Published In

Volume / Issue

  • 12 / 4

Start / End Page

  • 641 - 664

PubMed ID

  • 12687917

Pubmed Central ID

  • 12687917

International Standard Serial Number (ISSN)

  • 1052-5149

Digital Object Identifier (DOI)

  • 10.1016/s1052-5149(02)00027-8


  • eng

Conference Location

  • United States